2016 American Transplant Congress
Initial Evaluation of Use of NAT in Assignment of CMV and EBV Infection Status in Children Awaiting Solid Organ Transplant.
Medicine, University of Alberta, Edmonton, Canada.
Purpose: The presence of passive antibodies, transfusion-acquired or maternal in infants, can make serologic determination of pre-transplant CMV and EBV status in children unreliable. We…2016 American Transplant Congress
NKG2A-Expressing Natural Killer Cells Dominate the Response to Latent Epstein-Barr Virus Infection.
Introduction: EBV infection elicits a robust host immune response in healthy, immunocompetant individuals. EBV immunity is essential for preventing EBV-associated lymphomas in transplant recipients, including…2016 American Transplant Congress
Long-Term Outcomes in Epstein-Barr Virus (EBV)-Positive Patients Receiving Belatacept (Bela) or Cyclosporine (CsA) in BENEFIT-EXT.
At 7 yrs post transplant in BENEFIT-EXT (NCT00114777), bela-treated pts had similar graft survival and improved renal function vs CsA-treated pts. Bela is indicated for…2016 American Transplant Congress
Identification of MicroRNAs in EBV+ B Cell Lymphomas and Secreted Exosomes.
Division of Abdominal Transplantation, Dept. of Surgery, Stanford University, Stanford.
Introduction Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of organ transplantation commonly associated with Epstein Barr virus (EBV) infection. EBV viral loads are…2015 American Transplant Congress
Clinical and Virologic Outcomes in High-Risk Adult EBV D+/R- Organ Transplant Recipients
Background:EBV D+/R- organ transplant recipients are a high risk group for developing PTLD. This subgroup of patients has been primarily evaluated in pediatric populations with…2015 American Transplant Congress
Epstein Barr Virus Modulates Host Cell MicroRNA-194 to Promote IL-10 Production in B Cell Lymphomas
Surgery/Division of Abdominal Transplant, Stanford University School of Medicine, Stanford, CA.
Epstein Barr virus (EBV) infection is associated with the development of post-transplant lymphoproliferative disorder (PTLD) which can manifest as aggressive B cell lymphomas in transplant…2015 American Transplant Congress
Post-Transplant Lymphoproliferative Disorders Following Alemtuzumab Induction in Kidney Transplantation
Renal and Transplant Centre, Imperial College Healthcare NHS Trust, London, England, United Kingdom.
Post-Transplant Lymphoproliferative Disorder (PLTD) is a well-recognised serious complication in renal transplant recipients. Induction with lymphocyte depleting agents such as thymoglobulin has been associated with…2015 American Transplant Congress
B Cell MicroRNA as Biomarkers for Epstein-Barr Virus Associated Post-Transplant Lymphoproliferative Disorder
Surgery/Division of Abdominal Transplant, Stanford University School of Medicine, Stanford, CA.
Post-transplant lymphoproliferative disorder (PTLD) is a potentially fatal complication of organ transplantation and is commonly associated with Epstein Barr virus (EBV) infection. EBV viral loads…2015 American Transplant Congress
Genetic Diversity Epstein-Barr Virus Latent Gene EBNA-1 Among Transplant Patients and Patients With Infectious Mononucleosis
Introduction:-The distribution of Epstein Barr Virus (EBV)-associated pathologies varies worldwide. It is associated with the majority of cases of post-transplant lymphoproliferative disorder (PTLD). The EBNA-1…2015 American Transplant Congress
Preemptive Rituximab Therapy of Epstein-Barr Virus (EBV) Infection to Prevent Post-Transplant Lymphoproliferative Disease (PTLD) After Pediatric Solid Organ Transplantation (SOT)
Purpose: More than 90% of pediatric PTLD after solid organ transplantation is associated with EBV infection. Reduction in immunosuppression is the first step to prevent…
- « Previous Page
- 1
- …
- 7
- 8
- 9
- 10
- Next Page »